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Abstract. The binding activity of the AP-1 (FOS/JUN) 
complex to a negative regulatory element on the c-myc 
promoter was investigated in 7 tumour- versus normal lung 
specimens and it correlated with c-myc expression. AP-1 
levels were found elevated in two samples representing stage 
I progression of the disease, while in three stage III tumour 
samples, the AP-1 binding activity was equal or slightly 
elevated compared with their normal adjacent tissue. 
Southern blot analysis revealed amplified c-myc in all three 
cases of stage III tumours. These results suggest that there is a 
negative correlation between FOS/JUN binding on c-myc 
promoter and the expression of c-myc during the progression 
of the disease, further supporting the fundamental role of AP-1 
on c-myc regulation. 
Introduction 
The c-myc proto-oncogene encodes for two highly conserved 
nuclear phosphoproteins p62 and p64 involved in cellular 
proliferation and differentiation (1). Alteration οι c-myc 
expression, due to proviral insertion, chromosomal 
translocation and gene amplification, leads to quantitative 
and/or qualitative changes in c-MYC protein and has been 
correlated with the development of several types of 
malignancies in a wide range of species (2). Particularly in 
humans, chromosomal translocations involving the c-myc 
and the immunoglobulin heavy and light chain genes has 
been directly related to the development of Burkitt's 
lymphomas (3), while amplification of c-myc has been 
observed in several cases in lung, breast and head and neck 
cancer (reviewed in ref. 4). Furthermore, the expression of c-
myc has been found elevated in stomach, colorectal and 
cervical cancer (4) and in agressive myelomas (5). 
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The regulation of c-myc expression is complex and is 
controlled not only at the level of transcription, by both 
positive and negative m-acting regulatory elements, but also 
at the post-transcriptional level ( 1 ). 
The c-fos oncogene is known to participate in 
transcriptional regulation through formation of a c-fos:c-jun 
heterodimer protein known as the AP-1 complex (for a 
review see ref. 6). The AP-1 complex has been reported to 
participate in the process of differentiation (7,8) and may 
also control the expression of genes involved in cellular 
proliferation (6). Recently, Hay et al found a Negative 
Regulatory Element (NRE) within the c-myc promoter region 
which contains an AP-1 binding site (9). Herein we report on 
the AP-1 binding activity from tumour and adjacent normal 
lung specimens to the NRE of c-myc, as a possible 
mechanism or part of a mechanism regulating c-myc 
expression in lung cancer. 
Materials and methods 
Tissue specimens and cell lines. Tumour and adjacent normal 
lung tissue specimens were obtained from patients who had 
undergone lung surgery at the Metaxa Hospital, Pireas, 
Greece. None of these patients had previously received any 
chemotherapy. The histopathological type, the stage of 
differentiation and the pTNM of tumour of lung cancer 
patients are given in Table I. 
The HeLa cell line used in this study, was continuously 
maintained in RPMI-1640 (Gibco) with 50 μg/ml 
streptomycin and 300 μg/ml penicillin, supplemented with 
10% fetal calf serum (Flow), at 37°C in a 5% C0 2 atmosphere. 
Preparation of nuclear extracts. Nuclear extracts from tissue 
specimens were prepared as previously described (8). 
Briefly, tissues were cut into pieces, homogenised with a B-
type Dounce homogenizer in hypotonic buffer (25 mM 
TrisHCl, pH 7.5, 5 mM KCl, 0.5 mM MgCl2, 0.5 mM 
dithiothreitol (DTT) and 0.5 mM PMSF), centrifuged at 
2,000 χ g, washed three times with isotonic buffer (25 mM 
TrisHCl, pH 7.5, 5 mM KCl, 0.5 mM MgCl2, 0.1 M sucrose, 
0.5 mM DTT and 0.5 mM PMSF), and resuspended in 
nuclei extraction buffer (25 mM TrisHCl, pH 7.5, 1 mM 
EDTA, 0.1% Triton X-100, 0.5 mM DTT, 0.5 mM PMSF 
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Figure 1. Regulatory elements and transcription factor binding sites on the c-myc promoter. The AP-1 binding site is located whithin an NRE domain of c-myc 
promoter (9). 
Table I. pTNM, stage of differentiation and histopathological 
type of tumour of lung cancer patients. 
Patient no. 
1 
2 
3 
4 
5 
6 
7 
pTNM 
T2N1M0 
T3N0M0 
T2N1M0 
T3N1M0 
T2N0M0 
Τ1 NOMO 
T3N2M0 
Stage of 
differentiation 
II 
III 
II 
III 
I 
I 
III 
Histopathological 
type of lung tumour 
adenocarcinoma 
squamous 
SCLC 
squamous 
squamous 
adenocarcinoma 
SCLC 
and 0.6 M KCl). The nuclei were inverted slowly for 30 min 
and the extract clarified by centrifugation at 2.5 χ IO4g for 60 
min at 4°C. Nuclear extracts were stored at -70°C. Protein 
estimation was performed at 595 nm using the Biorad Protein 
Assay (Biorad). 
Synthesis of oligonucleotides and gel retardation assays. The 
myc AP-l oligonucleotide 5'-CCTGCGATGATTTATACTC 
ACAGG-3' contains the AP-1 binding site of the NRE domain 
of the human c-myc promoter (-342 to -313) (9) (Fig. 1). The 
E3API oligonucleotide 5'-CCGAAGTTCAGAT GACTA 
ACTCAGGG-3' representing the region between nucleotides 
-81 and -103 of the EIA inducible E3 promoter (10) 
containing an AP-1 binding site, was used for competition 
experiments. Both oligonucleotides were synthesized on an 
Applied Biosystems 381A DNA synthesizer. 
Single stranded complementary oligonucleotides were 
annealed, end-labelled using γ-32Ρ-ΑΤΡ (Amersham) and T4 
polynucleotide kinase (Boehringer) and run on an 8% 
Polyacrylamide gel to test the annealing. 
The binding reaction mixture contained 10 mM Hepes 
(pH 7.9), 0.2 mM EDTA, 94 mM NaCl, 0.1 mM PMSF, 0.1 
ng/ml BSA, 4% glycerol, 3 μg poly(dl-dC) (Pharmacia), 0.2-
1.0 ng 32P-labelled DNA and 20 μg nuclear extracts (except 
when otherwise indicated). The reaction mixture was left on 
ice for 30 min. Then, reaction mixtures were loaded onto a 
5% Polyacrylamide gel (29:1 acrylamide: N,N'-methylene 
bisacrylamide, Serva). Gels were run at 4°C in 0.55 X TBE, 
dried and exposed to X-ray film for autoradiography (Fuji). 
The rabbit monoclonal antibody FOS 388 used in this 
study was a generous gift of Dr D.A.F. Gillespie (Beatson 
Institute for Cancer Research, Glasgow, UK). 
Extraction of DNA and Southern blot analysis. DNA extracts 
from tissue specimens were prepared as described by 
Sambrook et al (11), slightly modified as follows: after the 
isolation of nuclear proteins as described above, the debris, 
which contained the cellular DNA, was incubated O/N in 
lysis solution (10 mM EDTA, 10 mM TrisHCl, pH 7.8, 150 
mM NaCl, 0.5% SDS and 100 μg/ml proteinase-K) at 37°C. 
After two phenol/chloroform/ isoamylalcohol extractions, the 
aqueous phase was removed and incubated for 2 h with 100 
μg/ml pancreatic RNase (Sigma) at 37°C and for an 
additional 2 h period with 100 μg/ml proteinase-K 
(Boehringer) followed by phenol/ chloroform/isoamylalcohol 
extraction twice. The aqueous phase was then removed and 
the DNA was precipitated with ethanol. The DNA was 
washed with 70% EtOH, dried briefly, resuspended in sterile 
water and estimated photometrically at 260 nm using an LKB 
4054 spectro-photometer. 
10 μg of each DNA sample was digested O/N with 100U 
of Hindlll (Boehringer), precipitated with ammonium acetate 
and ethanol, dried briefly and resuspended in 20 μΐ of sterile 
water. Samples were then loaded on a 0.7% agarose gel and 
run O/N at 30V in 1 X TBE running buffer. 
For Southern blotting we followed the HybondN+ 
protocol (Amersham) using 20 X SSPE buffer for transfer. 
After blotting, DNA was fixed by baking the membrane at 
80°C for 2 h. 
Pre-hybridization with 5 X SSPE, 5 X Denhardt's 
solution, 50% formamide and 0.5% (w/v) SDS for 6 h in 
42°C, was followed by overnight hybridization. The probes 
used were the the 1.4 Kb Clal/EcoRI fragment of plasmid 
pMC41-3RC, carrying the third exon (EIII) of the human c-
myc gene (12) and the 6.4 Kb BamHI/BamHI fragment of 
plasmid pHo6Nl, carrying the human Η-ras gene (13). 
ONCOLOGY REPORTS 1: 139-143. 1994 141 
S ". 
STAGE II 
PATIENT No I 1 2 3 4 5 6 7 
T N T N T N T N T N T N T N 
Free DNA — I 
μg of HeLa 
protein extracts 10 20 Free DNA 
PROBE wvcAP-1 PROBE mvcAP- Free DNA 
mvcAP-1 probe 
Figure 2. (a) Binding of nuclear factors from HeLa cells to mycAP-1 oligo. 
Only the b complex has been shown to be a FOS/JUN (AP-1) protein (see 
text), (b) Effect of FOS antibody (lane 2) and wvcAP-1 cold competitor 
(lane 3) on c-myc DNA-protein complexes in a gel retardation assay. 
Extracts from HeLa cells were used. 
DNA-inserts were labelled with 3 2 P dCTP (Amersham) using 
the r a n d o m p r i m e d D N A labe l l ing kit of B o e h r i n g e r 
Mannheim. 
Membranes were finally washed twice in 2 X SSPE, 0.1 % 
SDS in room temperature for 30 min, twice in 1 X SSPE, 
0 . 1 % SDS for 20 min at 42°C and once in 0.5 X SSPE, 0 . 1 % 
SDS at 42°C for 15 min, followed by exposure to X-ray film 
(Fuji) with an intensifying screen. 
Results 
The NRE of c-myc is located in position -350 to -290 relative 
to transcription start site PI and has been reported to contain 
the recognition site for the cellular transcription factor AP-1 
(ref. 9 and Fig. 1). 
When crude extracts from HeLa cells, which are known 
to o v e r e x p r e s s the F O S / J U N h e t e r o d i m e r prote in, are 
incubated with the mvcAP-1 oligonucleotide, three complexes 
a, b and c are formed (Fig. 2a and ref. 9). Only the b-complex 
has been shown to represent the FOS/JUN protein (9). Indeed, 
antibody against the FOS protein eliminated the b-band in 
extracts from both HeLa cells (Fig. 2b, lane 3) and lung 
tumour specimen no. 3 (Fig. 3a, lane 2). In order to test 
fur ther the speci f ic i ty of the b i n d i n g , we p e r f o r m e d 
competit ion assays with excess (200x) of myc AP-1 and 
E 3 AP-1 cold ol igonucleotides. Excess of cold mvcAP-1 
inhibited the binding of protein-DNA complexes b and c in 
both the HeLa cells (Fig. 2b, lane 2) and in the protein extracts 
from specimen no. 3 (Fig. 3b, lane 3). while cold E3AP-1 
inhibited mainly the formation of complex b (Fig. 3b, lane 4). 
By per forming gel re tardat ion assays with nuc lear 
extracts from tumour and adjacent normal lung specimens, 
we observed an altered AP-1 binding to the c-myc NRE. 
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Figure 3. (a) Gel retardation assay with extracts from tumour and adjacent 
normal lung tissue, (b) Effect of FOS antibody (lane 2) and excess of cold 
mvcAP-1 and Ε,ΑΡ-1 (lanes 3 and 4) on c-myc DNA-protein complexes in 
gel retardation assay. Extracts from tumour specimen no. 3 were used. 
Elevated AP-1 levels were observed in two stage I tumours 
(Fig. 3a, samples 5, 6), while in the three stage III tumours, 
the AP-1 levels were equal or slightly elevated compared 
with the normal tissue (Fig. 3a, samples 2, 4 and 7). The 
latter three specimens revealed amplified c-myc in Southern 
blot analysis (Fig. 4, lanes 2,4,7). One of the two stage II 
lung tumours presented low AP-1 levels, while in the other, 
the AP-1 activity, although elevated, was lower than that of 
the stage I tumours (Fig. 3a, samples 1 and 3). 
Discussion 
The role of the c-myc o n c o g e n e in the progress ion of 
carcinogenesis has been extensively investigated in a range 
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Figure 4. Southern blot analysis revealed c-myc amplification in three stage 
III samples (samples 2,4,7). 10 μg of DNA from cases 1-7 was digested with 
Hindlll and analyzed with (a) c-myc exon 3 probe and (b) c-H-ras probe. 
The same filter was used for the two hybridizations. Autoradiographic 
exposure time was approximately 4 days. Lambda phage DNA, digested 
with Hindlll, was used as a molecular weight marker. Densitometrie 
analysis of the autoradiograph, normalized to H-ras, which is known not to 
be amplified in lung tumours (24), revealed three samples (patient numbers 
2,4 and 7) with c-myc levels at least twice those of H-ras. 
of human solid tumours. Genetic alterations of c-myc is 
believed to be important in the progression of these cancers 
and may be of use as a prognostic indicator (4). 
In lung cancer in particular, amplified c-myc has been 
found in primary tumours and cell lines (14,15) and has been 
correlated with poor prognosis (16). Understanding the 
mechanism of c-myc regulation in these cases is of great 
importance. 
The modulation of c-myc expression is complicated and is 
accomplished on both transcriptional and post-transcriptional 
level. The c-myc NRE, located within the c-myc promoter 
region (Fig. 1), participates in the modulation of the 
oncogene expression through binding of three transcription 
factors (8,9). One of them (complex b, Figs. 2 and 3) is the 
heterodimer protein FOS/JUN (AP-1). That NRE has been 
shown to be important for c-myc expression following 
platinum and anthracycline exposure of Friend cells (17,18), 
while the altered FOS/JUN binding activity we have recently 
reported, during the HMBA-induced differentiation of mouse 
erythroleukemic cells (8), further supports the contribution of 
the AP-1 protein to c-myc regulation. 
In this study, we performed gel retardation assays with 
protein extracts from lung tumour and adjacent normal tissue, 
to examine the AP-1 levels bound to the c-myc NRE and 
correlated these results with c-myc expression. 
We found elevated FOS/JUN levels in only three out of 
seven samples, that is two stage I and one stage II lung 
tumours, while in the other four samples the AP-1 activity 
was equal or slightly elevated compared with the normal 
tissue. Three of the latter cases corresponded to stage III 
tumours and presented amplified c-myc, as revealed by 
Southern blot analysis (Fig. 4). Therefore, a good correlation 
between stage of differentiation and AP-1 binding activity 
exist on c-myc NRE; the higher the stage, the lower the 
FOS/JUN levels bound to that region. Recently, 
Linardopoulos et al, using the same model of lung cancer, 
showed an opposite pattern of AP-1 binding to an AP-1-like 
site in the promoter region of retinoblastoma (Rb) gene ( 19). 
In that study, the increased binding was in accordance with 
the development of tumour differentiation. It is therefore 
possible that the transcription factor AP-1 plays a different 
role in the expression of Rb and c-myc during progression of 
the malignancy of the lung. 
The expression of the c-myc gene is considered to be 
crucial in cellular proliferation (20); lymphocytes stimulated 
with mitogens rapidly increased their expression of c-myc 
mRNA as they entered into cell cycle (21), while the c-MYC 
protein has been shown to bind to an autonomously 
replicating sequence (ARS) in eukaryotic cells and thus 
promoting its replication (22). There is also evidence of high 
proliferative activity in stage III myeloma cells in agressive 
myeloma with overexpression of c-myc (5,23). Taking into 
account these reported experimental data, our results suggest 
that the low levels of AP-1 bound to the NRE of c-myc could 
contribute to the induction of c-myc expression and also to 
the proliferative activity which is characteristic of the late 
stages of tumour development. 
In conclusion, despite the small number of tumours 
tested, our results further support a role of the heterodimer 
protein AP-1 in tumour progression and also in 
transcriptional regulation of c-myc expression. It is suggested 
that the decreased levels of FOS/JUN bound to the c-myc 
NRE in high stages of tumour differentiation could 
contribute to the overexpression of the c-myc oncogene, 
which, in turn, could affect the cellular proliferative potential 
and clinical outcome. 
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